DBV Technologies, a clinical-stage biopharmaceutical company focused on treatments for food allergies, announced the completion of the last patient visit in its Phase 3 VITESSE clinical trial evaluating the Viaskin Peanut patch in peanut-allergic children aged 4–7 years.
With the double-blind, placebo-controlled treatment phase now complete, the company confirmed it is on track to report topline results in Q4 this year.
“Last patient last visit represents a very important milestone for DBV, as it brings us one step closer to the potential of bringing this treatment option to peanut-allergic children, their physicians and caregivers, if approved,” said Daniel Tassé, CEO of DBV Technologies. “We’re grateful to investigators, our internal teams, and especially the patients and caregivers for their commitment. We look forward to sharing topline results this quarter.”
About the VITESSE Phase 3 Trial
- Designed to assess the efficacy and safety of the Viaskin Peanut patch
- 654 children enrolled, randomized 2:1 (active vs. placebo)
- Conducted over 12 months
- Includes participants across 86 sites in the U.S., Canada, Europe, the U.K., and Australia
- Currently the largest interventional study ever conducted in peanut allergy
About DBV Technologies
DBV Technologies is developing therapeutic options for food allergies and other immunologic diseases with significant unmet needs. The company’s lead investigational platform, the VIASKIN epicutaneous patch, is designed to deliver allergens through the skin to modulate the immune system. Food allergies can trigger severe reactions, including life-threatening anaphylaxis, and remain a major global health concern.
